key: cord-0930818-fvupjy6o authors: Akinosoglou, Karolina; Paliogianni, Foteini; Spyridonidis, Alexandros; Symeonidis, Argiris; Alexopoulos, Leonidas G.; Ziazias, Dimitrios; Kouraklis‐Symeonidis, Alexandra; Marangos, Markos; Gogos, Charalambos title: SARS‐CoV‐2 persistence and non‐protective immunity in infected haematological patients date: 2020-11-20 journal: Br J Haematol DOI: 10.1111/bjh.17212 sha: 8b597c1304f60816be9d220b4aa5f5e2819818f7 doc_id: 930818 cord_uid: fvupjy6o nan A 35-year-old with a history of ALL was referred to our department on 26 March 2020 due to a positive SARS-CoV-2 PCR (polymerase chain reaction) test; at the time asymptomatic. He had previously received a cycle of R-hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, adriamycin, dexamethasone), including anti-CD20 monoclonal antibody (rituximab), 14 days prior to referral. On 8 April the patient presented with fever, hypoxaemia and bilateral infiltrates, indicative of pneumonia. A positive PCR test for SARS-CoV-2 established the diagnosis of COVID-19. The patient's condition and various regimen intolerances did not allow for any experimental therapeutic interventions, besides common antibiotics and oxygen supplementation. The patient followed an uncomplicated course, showing gradual improvement and decline in viral load (Fig 1) . At the same time, SARS-CoV-2 antibody isotypes (IgG/IgA/IgM) against the N, S1 and RBD antigens were assessed by multiplex N-RBD-S1 assay (Protatonce Ltd), based on Luminex xMAP technology, and were found to be present, as shown in Table 1 . The patient was then discharged to continue his treatment with a second R-hyper-CVAD cycle for his underlying disease, approximately one month after a negative PCR test on 25 May. On 2 July, the patient was readmitted with severe SARS-CoV-2 pneumonia, as confirmed by a positive PCR test for SARS-CoV-2, exhibiting high viral loads (Fig 1) , but revealing an adequate IgG response against S1 and RBD (Table 1 ). Similar to the first admission, we exclusively followed supportive and antibiotic therapy, until the patient recovered and was discharged 25 days later, with negative PCR. We present the first case of a SARS-CoV-2 seroconverted haematological patient presenting with two consecutive episodes of severe COVID-19 pneumonia, following intense intermediate chemotherapy. Our case raises two important issues: first, the possibility of re-infection with SARS-CoV-2, despite antibody presence; and second, that of possible viral persistence in immunocompromised patients. A number of studies have previously reported evidence of SARS-CoV-2 're-activation'. 7 However, a false negative PCR test and a prolonged nucleic acid conversion, rather than recurrence, seems to be the case in these patients. 8 In our report, patients presented with typical clinical manifestations and detectable viral amplification while undergoing intense chemotherapy. Moreover, a gradual decrease in viral gene replication, reflecting decreasing viral activity, was noted in consecutive samples, in line with symptom resolution during both admissions. This finding, in the absence of antiviral or other COVID-19 related regimen administration, indicates primary self-mediated infection control, driven by immune reconstitution following courses of chemotherapy. Even though antibodies were detected during both admissions, it is open to discussion whether specific anti-SARS-CoV-2 antibodies offer protection or whether a specific correspondence threshold is required. Antibodies against the S1 domain of spike protein, the RBD and the NP have been detected in previously infected patients. 6 Although the anti-NP and S1generated antibodies show high sensitivity, specificity increases with RBD-specific antibodies. 9 The use of antigen combinations hereby exhibits improved performance and manages to discriminate between cases of cross-reactivity and/or cases of prior other coronavirus infections. 6 As per manufacturer interpretation rule (Protatonce Ltd), the patient presented positive anti-SARS-CoV-2 antibodies (green shading) against S1 and receptor-binding domain (RBD), but not nucleoprotein. First and second admission sampling was performed on 30 March and 4 July, respectively. specific antibodies show greater potency to neutralise infection, but may not be enough to ensure viral clearance. It is possible that anti-NP presence is pivotal to confer immunity and also be thymus-dependent, as occurs in the paediatric population. 10 In the presence of impaired antigen presentation, due to the lack of B cells following rituximab administration, this could not be accomplished in our patient. Based on the knowledge of other corona viruses, we hypothesise that SARS-CoV-2 could evade an immune response in patients with a defective innate and adaptive humoral and cellular response, in combination with high viral loads, uncontrolled distal viral spread via exosome production and/ or susceptible haplotypes. 11 Although coronaviruses are not known to undergo latency, the possibility of abortive or restrictive infections in combination with a hidden unknown reservoir, resulting in chronic infection, should be explored. We argue that SARS-CoV-2 infection may show persistence in immunocompromised haematological hosts. A single similar case has recently been reported in an immunocompromised haematological patient with chronic leucocyte leukaemia; however, no antibodies were ever detected in this case, possibly due to immune impairment. 12 However, as shown herein, detectable antibodies may not be neutralising or confer immunity, and attending physicians should therefore be alert to symptom exacerbation, suggesting COVID-19 disease re-activation, especially duringor briefly followingtimes of chemotherapy administration. Comprehensive data on the management and outcome of patients with immune deficiencies remains scarce, even though a prolonged course of 10 days 13 or repeated courses of remdesivir administration have been reported. 12 A combination with other regimensincluding convalescent plasmahas been utilised with favourable results; this cannot determine, however, whether it was immune reconstitution and spontaneous resolution, or our intervention which was responsible for the optimal outcomes. 12, 14 Further studies in haematological patients are warranted. This study has been conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice, and approved by the local ethics committee and IRB. The patient reported on in this study signed an informed consent form to have his data anonymously analysed, utilised and published. Data can be made available upon request, according to GDPR. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy COVID-19 in persons with haematological cancers COVID-19 in immunocompromised hosts: what we know so far Compagno FEHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent plasma using a coronavirus antigen microarray Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response COVID-19: unanswered questions on immune response and pathogenesis Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy Remdesivir for the treatment of Covid-19 -preliminary report Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review The authors would like to thank (a) Drs Konstantinos Tsiotsios, Christos, Davoulos, Alexandros Tousis, Gerasimos Karantzogiannis, and Stamatia Tsoupra, involved with the patient's COVID-19 management, (b) the Haematology Department and especially Drs Evangellia Tzouvara and Vasileios Lazaris, for management of the patient's haematologic disease, (c) Drs Fevronia Kolonitsiou, Myrto Christophidou, Sophia Vamvakopoulou, Iris Spiliopoulou, Vasiliki Stamouli, who were involved in the COVID-19 diagnostic assessment.